%0 Journal Article
%K Humans
%K BNT162 Vaccine
%K *COVID-19/epidemiology/prevention & control
%K *COVID-19 Vaccines/adverse effects
%K SARS-CoV-2
%K *Thrombocytopenia/epidemiology/etiology
%K *Thrombosis/epidemiology/etiology
%K Vaccination/adverse effects
%K *Venous Thromboembolism/epidemiology/etiology
%K United Kingdom
%B Nat Commun
%D 2022
%G eng
%M 36418291
%P 7167
%R 10.1038/s41467-022-34668-w
%T Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom
%V 13
%2 PMC9684520 Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen and UCB Biopharma. The remaining authors declare no competing interests.
%7 2022/11/24
%@ 2041-1723